Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Health officials report 14 Legionnaires' disease cases in Florida, gym connection suspected - 2More than half way to the moon, the Artemis II astronauts are grappling with a toilet problem
- 3Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- 4The Way to Business: Startup Illustrations Learned
- 5Brazil judge orders government to add JBS subsidiary to 'dirty list' for slavery
- Freed whale gets stranded again off German coast
- Turkey’s intel chief lays out country’s vision for Middle East, world
- Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- Survey: Protected And Versatile Men's Razor
- Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- 6 Exercises to Anticipate in 2024
- Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
- Paraplegic engineer becomes the first wheelchair user to blast into space
- How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
